We don't need to access the brain to treat cognitive decline
In the quiet machinery of aging, the blood itself may carry the seeds of forgetting. Researchers at the University of California have identified a protein called granzyme K, released by aging immune cells, as a key driver of cognitive decline — one that operates not from within the brain, but from the circulatory system that surrounds it. In mice, blocking this protein restored memory and learning, suggesting that the boundary between body and mind in the story of aging may be far more permeable than medicine has long assumed.
- Aging immune cells circulating in the blood — not just changes inside the brain — are actively eroding memory and learning in older animals.
- The protein granzyme K, secreted by aged CD8+ lymphocytes, appears to cross into the brain and suppress the hippocampus's ability to form new connections.
- When young mice were surgically linked to older ones and exposed to aged immune cells, their cognitive performance declined and key synaptic genes were silenced.
- Blocking granzyme K or suppressing the immune cells responsible reversed memory decline — even in animals already showing age-related deterioration.
- The finding reframes treatment strategy: drugs may not need to breach the notoriously difficult blood-brain barrier, because the target is already circulating in the blood.
A research team at the University of California has identified a protein in the blood — granzyme K — that appears to drive age-related memory loss, and shown that blocking it can restore cognitive function in aging mice. The discovery, published in Nature and rooted in work begun in 2018, shifts the understanding of brain aging away from a purely neurological problem toward one with systemic, blood-borne origins.
The culprits are aged CD8+ lymphocytes, immune cells that accumulate over a lifetime and release granzyme K into the bloodstream. The protein appears to reach the hippocampus — the brain's memory center — and interfere with synaptic plasticity, the mechanism by which the brain forms and reinforces connections. To confirm the link, researchers used parabiosis, surgically joining the circulatory systems of young and old mice. Young animals exposed to aged immune cells showed measurable cognitive decline and suppressed synaptic gene activity. The effect reversed when the immune cells were blocked or granzyme K was directly inhibited.
Lead researcher Saul Villeda noted the therapeutic implication plainly: treatment may not require reaching the brain at all. Targeting circulating immune factors in the blood could be enough to influence memory. Outside researchers called the finding genuinely novel, particularly the demonstration that immune cells outside the brain could shape its function so directly.
The team acknowledges that granzyme K is one piece of a larger puzzle — brain aging involves multiple circulating factors, and the precise brain-barrier cells that respond to the protein are still unknown. But granzyme K's role appears both necessary and sufficient for the cognitive decline observed. The next frontier is determining whether the same mechanism operates in humans, and whether drugs targeting this protein could one day slow or reverse memory loss in aging people.
A team at the University of California has traced a path from the bloodstream to memory loss in aging brains—and found a way to reverse it. In experiments with mice, researchers discovered that immune cells circulating in the blood of older animals actively damage cognitive function by releasing a protein called granzyme K. More importantly, when they blocked this protein, memory and learning improved, even in animals already showing signs of age-related decline.
The work, published in Nature and building on research that began in 2018, centers on a specific type of immune cell: aged CD8+ lymphocytes. These cells, which accumulate as we grow older, secrete granzyme K into the bloodstream. The protein then appears to cross into the brain and interfere with the hippocampus, the region responsible for forming new memories. The finding is striking because it suggests that cognitive aging is not simply a problem locked inside the brain—it is partly driven by changes happening elsewhere in the body.
To establish this connection, the researchers used a surgical technique called parabiosis, which involves connecting the circulatory systems of a young mouse and an old mouse. This allowed them to observe whether immune cells from an older animal would age the cells of a younger one, and vice versa. They found that when young mice were exposed to aged CD8+ lymphocytes, their memory performance declined and key genes involved in synaptic plasticity—the brain's ability to form and strengthen connections—were suppressed. The effect was not permanent. When the researchers blocked the CD8+ cells or inhibited granzyme K specifically, cognitive function rebounded.
In older mice given direct inhibitors of granzyme K, performance on memory tests improved significantly. The team also demonstrated that even partial suppression of CD8+ cell activation was enough to prevent cognitive decline in young animals, confirming that the immune cells themselves, not some other age-related factor, were responsible. Saul Villeda, a neuroscientist at UC San Francisco and a lead author, noted the practical implication: "We don't even need to access the brain to begin treating cognitive decline. We can block certain substances in the blood to influence memory."
The discovery opens a new avenue for intervention. Rather than developing drugs that must cross the blood-brain barrier—a notoriously difficult challenge in neurology—researchers could target circulating immune factors. Paloma Navarro Negredo, a neuroimmunologist at the Swiss Federal Institute of Technology in Lausanne, called the finding "completely new," highlighting that the influence of these cells on the brain from outside the organ itself had not been previously understood.
The researchers acknowledge that granzyme K is not the only factor driving cognitive aging. Brain aging likely results from a combination of circulating substances, and the exact cells in the brain's barrier that respond to granzyme K remain to be identified. But the protein's role appears decisive: it is both necessary for the cognitive decline observed in aged mice and sufficient to cause decline in young ones when present in sufficient quantities. The next steps will involve testing whether similar mechanisms operate in humans and whether drugs targeting granzyme K could slow or reverse memory loss in aging people.
Citações Notáveis
We don't even need to access the brain to begin treating cognitive decline. We can block certain substances in the blood to influence memory.— Saul Villeda, neuroscientist, UC San Francisco
This finding reveals something completely new about how cells outside the brain influence it from a distance.— Paloma Navarro Negredo, neuroimmunologist, Swiss Federal Institute of Technology Lausanne
A Conversa do Hearth Outra perspectiva sobre a história
So the immune system is actually making us forget things as we age?
Not the immune system itself—but a specific type of immune cell that changes with age. These CD8+ lymphocytes are doing their job, but in older animals, they're releasing a protein that damages memory circuits in the brain.
And you can just block that protein and memory comes back?
In the mice, yes. When they inhibited granzyme K, cognitive function improved noticeably. The memory deficits weren't permanent; they were reversible.
Why is it significant that you don't have to touch the brain directly?
Because the blood-brain barrier is one of the hardest obstacles in neurology. Most drugs can't cross it. But if the problem originates in the blood, you can treat it there—simpler, safer, fewer side effects.
How did they prove the immune cells were actually causing the problem and not just present during aging?
They transferred old immune cells into young mice. The young mice then showed memory decline. That's causal evidence. Then they blocked the cells or the protein, and the decline reversed.
Is this the same in humans?
That's the open question. The mechanism appears to be there—we know granzyme K exists in human blood and increases with age. But they haven't yet tested whether blocking it helps human cognition.
What's the catch?
Granzyme K isn't the only factor. Brain aging is probably multifactorial. And they still don't fully understand which cells in the brain are actually responding to this protein. It's a piece of a larger puzzle.